Targeting the microbiota in pharmacology of psychiatric disorders
Combining cagrilintide with tirzepatide could theoretically produce 20-30% body weight loss by targeting three distinct pathways (GIP, GLP-1, and amylin), but the lack of clinical data means dosing protocols are speculative, side effect profiles unknown, and safety unclear
There are many potential side effects and a few of them include: thyroid cancer in animals, pancreatitis, gastroparesis, gall bladder disease, GI upset (nausea, vomiting, diarrhea, constipation), maybe depressed mood, diabetic retinopathy, low sugars, vision loss
These treatments are intended for people with medical reasons for weight loss, rather than short-term or cosmetic goals
Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome in aging